Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030

The Neuromodulation Devices market is expected to grow at a static CAGR forecast till 2030 owing to growing prevalence of neurological disorders and rise in numbers of patients suffering from chronic pain.

The neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030 to reach USD 9.56 billion by 2030. The demand for neuromodulation devices is primarily driven by the growing prevalence of neurological disorders and the increasing number of patients suffering from chronic pain. Additionally, increasing research and development activities, along with collaborations among key players, are significantly contributing to market growth. The rising aging population further compounds this demand, as older adults are more susceptible to neurological conditions and chronic pain. These factors collectively position the neuromodulation devices market for positive growth during the forecast period from 2024 to 2030.

Neuromodulation Devices Market Dynamics:

The growing prevalence of neurological disorders is anticipated to significantly propel the market, driven by the widespread application of neuromodulation devices in their treatment. According to data provided by the World Health Organization (WHO) in March 2024, migraine and other headache disorders affected 3.1 billion people globally in 2021.

Data from the Parkinson’s Foundation in 2022 indicates that approximately 90,000 individuals are diagnosed with Parkinson's disease (PD) each year in the United States, with projections suggesting that the number of affected individuals will reach 1.2 million by 2030. As the prevalence of neurological conditions continues to rise, the demand for neuromodulation devices is expected to increase, further driving market growth.

Additionally, data from the WHO in June 2023 revealed that around 619 million people were living with lower back pain (LBP) in 2020, with projections indicating that this number is expected to rise to approximately 843 million cases by 2050 worldwide. This increase in LBP cases is primarily attributed to population growth and an aging demographic. Restorative neurostimulation devices are designed to trigger repeated contractions of the multifidus muscles, effectively restoring their strength and stabilizing the spine. As the prevalence of chronic pain continues to rise, the demand for neuromodulation devices is expected to increase, significantly propelling market growth.

Key players in the industry are increasingly focusing on research and development to create innovative neuromodulation systems, further enhancing market growth. For instance, in April 2024, Magnus Medical, Inc., a company specializing in therapeutic neuromodulation, launched the SAINT neuromodulation system specifically designed for treating major depressive disorders. This system utilizes structural and functional magnetic resonance imaging (MRI) scans to guide a proprietary algorithm that accurately identifies the precise anatomical targets for neurostimulation in individuals with major depression. By optimizing treatment effectiveness through targeted stimulation, this innovative approach aims to improve patient outcomes and enhance the overall efficacy of depression therapies. Such advancements are expected to significantly enhance patient outcomes and further drive market growth.

However, certain factors, such as the high cost of these devices and the risk of device-associated complications, may constrain the growth of the neuromodulation devices market.

Neuromodulation Devices Market Segment Analysis:

Neuromodulation Devices Market by Type (Invasive and Non-Invasive), Product (Spinal Cord Stimulators, Vagus Nerve Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Transcranial Magnetic Stimulators, and Others), Application (Pain Management, Neurological Disorder, Respiratory Disorders, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the neuromodulation devices market, spinal cord stimulators are expected to hold a significant market share during the forecast period. This is attributed to the growing patient population suffering from chronic pain, failed back syndrome, lower back pain, and complex regional pain syndrome (CRPS). According to data from the Centers for Disease Control and Prevention (CDC) in April 2023, it was estimated that 20.9% of adults, accounting for approximately 51.6 million individuals, were suffering from chronic pain. Of these, 6.9%, or about 17.1 million people, experienced high-impact chronic pain in 2021 in the United States, which significantly restricted their daily activities. Spinal cord stimulation devices are effective in treating various types of chronic pain, thereby driving segment growth and contributing to the overall expansion of the neuromodulation devices market.

Recent advancements in spinal cord stimulators, such as rechargeable batteries and wireless remote technology, are also contributing to segment growth. For instance, in December 2022, Abbott Laboratories launched the Eterna™ spinal cord stimulation (SCS) system for the treatment of chronic pain. The Eterna SCS system incorporates Abbott's proprietary BurstDR stimulation, which mimics the natural firing patterns found in the brain, providing superior pain relief. This neuromodulation device offers an optimized experience by allowing wireless charging as infrequently as five times per year. Such developments by key players are expected to drive market growth.

Overall, these factors are likely to fuel segment growth and foster the expansion of the neuromodulation devices market during the forecast period.

North America is expected to dominate the overall neuromodulation devices market:

North America is expected to dominate the overall neuromodulation devices market during the forecast period. This dominance can be attributed to the rising number of patients suffering from neurological disorders and increasing product development activities by key players. Additionally, the growing geriatric population is a significant factor contributing to the growth of the neuromodulation devices market in this region.

According to data provided by the Centers for Disease Control and Prevention (CDC) in April 2023, an estimated 6.7 million people aged 65 years or older were living with Alzheimer’s disease, with projections indicating this number could nearly triple, reaching 14 million by 2060 in the United States. The rising prevalence of various neurological disorders is likely to be a key driver for the growth of the neuromodulation devices market in North America.

Further supporting this trend, the CDC reported in May 2024 that approximately 3 million people were suffering from epilepsy in the United States in 2021. Such active cases encourage key players to develop neuromodulation devices specifically for epilepsy treatment. For example, in March 2021, NeuroPace, Inc. announced that it received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for its RNS® System, which is designed to treat idiopathic generalized epilepsy. The RNS System is a brain-responsive neuromodulation system that delivers personalized, targeted treatment directly at the seizure source and serves as adjunctive therapy for adults suffering from drug-resistant focal epilepsy. These factors are likely to drive significant growth in the neuromodulation devices market in North America.

Moreover, the Asia-Pacific region is poised for future growth in the neuromodulation devices market. This potential is driven by improving healthcare infrastructure, increasing per capita healthcare expenditure, rising disposable income, and a growing elderly population. Additionally, recent product development activities among key manufacturers aiming to expand their product portfolios in the APAC region will also boost the market. For instance, in 2021, Neurolief Ltd., a neurotechnology innovator, entered into an exclusive agreement with Sawai Pharmaceutical Co., Ltd. to develop and market Relivion®, a non-invasive brain neuromodulation device for migraine and depression in Japan. This device is designed for placement around the head, delivering targeted stimulation to the occipital and trigeminal nerves. This targeted stimulation generates a cumulative effect by releasing neurotransmitters in the brainstem, modulating brain networks, and ultimately aiding in pain management.

Neuromodulation Devices Market Key Players:

Some of the key market players operating in the neuromodulation devices market include Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and others.

Recent Developmental Activities in the Neuromodulation Devices Market:

• In January 2024, Boston Scientific Corporation announced that it had entered into a definitive agreement to acquire Axonics, Inc. for an amount of USD 3.4 billion. Through this acquisition, Boston Scientific expanded its neurostimulation device product portfolio with advanced technology development in sacral neuromodulation.
• In March 2022, Bioventus announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance to the next-generation StimRouter® Neuromodulation System for the treatment of chronic pain. StimRouter is a minimally invasive neuromodulation medical device comprising a thin implanted lead with a conductive electrode, an external electric field conductor (E-EFC), and the StimRouter Plus Mobile Application.
• In March 2021, Helius Medical received the US FDA approval for Portable Neuromodulation Stimulator approval for short-term treatment of gait deficit due to multiple sclerosis.
• In January 2021, Boston Scientific Corporation received FDA approval for its fourth-generation Vercise Genus Deep Brain Stimulation (DBS) System used to treat symptoms in patients with advanced Parkinson’s disease.

Key Takeaways from the Neuromodulation Devices Market Report Study

• Market size analysis for current Neuromodulation Devices Market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the Neuromodulation Devices market.
• Various opportunities available for the other competitors in the Neuromodulation Devices Market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current Neuromodulation Devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Neuromodulation Devices market growth in the coming future?

Target Audience who can be benefited from this Neuromodulation Devices Market Report Study

• Neuromodulation Devices product providers
• Research organizations and consulting companies
• Neuromodulation Devices related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Neuromodulation Devices
• Various end-users who want to know more about the Neuromodulation Devices Market and the latest technological developments in the Neuromodulation Devices Market.

Frequently Asked Questions for the Neuromodulation Devices Market:

1. What are Neuromodulation Devices?

• Neuromodulation devices, also known as neurostimulation devices involve the application of electrodes to the brain, the spinal cord, or peripheral nerves. These devices can increase or decrease the activity of the nervous system by generating necessary electrical stimulation.

2. What is the market for Neuromodulation Devices?

• The neuromodulation devices market was valued at USD 5.71 billion in 2023, growing at a CAGR of 8.95% during the forecast period from 2024 to 2030 to reach USD 9.56 billion by 2030.

3. What are the drivers for the Neuromodulation Devices market?

• The neuromodulation devices market is slated to witness prosperity owing to factors such as the growing prevalence of neurological disorders and the rise in the number of patients suffering from chronic pain. Increasing R&D activities and collaboration among key players and the rising aging population are the key factors that are responsible for contributing to the positive growth of the neuromodulation devices market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Neuromodulation Devices market?

• Some of the key market players operating in the neuromodulation devices market include Medtronic, Abbott Laboratories, Boston Scientific Corporation, LivaNova PLC, NeuroSigma, Inc., NEVRO CORP., Synapse Biomedical Inc., NeuroPace, Inc., Bioventus, Soterix Medical Inc., Neuronetics Inc., ALEVA NEUROTHERAPEUTICS, Magstim, SPR Therapeutics, Inc., Theranica Bio-Electronics Ltd., electroCore, Inc., Neuros Medical, Magnus Medical, Inc., Integer Holdings Corporation, Mainstay Medical, and others.

5. Which region has the highest share in the Neuromodulation Devices market?

• North America is expected to dominate the overall neuromodulation devices market during the forecast period from 2024 to 2030. This domination is due to the rise in several patients suffering from neurological disorders and increasing product development activities by key players. Additionally, the growing geriatric population is another key factor contributing to the growth of the neuromodulation devices market in this region.

This product will be delivered within 2 business days.